Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype.
Apolipoprotein E2, which has an R158 for C substitution, has reduced affinity for the LDL receptor and is associated with type III hyperlipoproteinemia in humans. Consistent with these observations, we have found that following adenovirus-mediated gene transfer, full-length apoE2 aggravates the hypercholesterolemia and induces hypertriglyceridemia in E-deficient mice and induces combined hyperlipidemia in C57BL/6 mice. Unexpectedly, the truncated apoE2-202 form that has an R158 for C substitution when expressed at levels similar to those of the full-length apoE2 normalized the cholesterol levels of E-deficient mice without induction of hypertriglyceridemia. The apoE2 truncation increased the affinity of POPC-apoE particles for the LDL receptor, and the full-length apoE2 had a dominant effect in VLDL triglyceride secretion. Hyperlipidemia in normal C57BL/6 mice was prevented by coinfection with equal doses of each, the apoE2 and the apoE2-202-expressing adenoviruses, indicating that truncated apoE forms have a dominant effect in remnant clearance. Hypertriglyceridemia was completely corrected by coinfection of mice with an adenovirus-expressing wild-type lipoprotein lipase, whereas an inactive lipoprotein lipase had a smaller effect. The findings suggest that the apoE2-induced dyslipidemia is not merely the result of substitution of R158 for C but results from increased secretion of a triglyceride-enriched VLDL that cannot undergo lipolysis, inhibition of LpL activity, and impaired clearance of chylomicron remnants. Infection of E(-)(/)(-)xLDLr(-)(/)(-) double-deficient mice with apoE2-202 did not affect the plasma cholesterol levels, and also did not induce hypertriglyceridemia. In contrast, apoE2 exacerbated the hypercholesterolemia and induced hypertriglyceridemia, suggesting that the LDL receptor is the predominant receptor in remnant clearance.
Kypreos
Kyriakos E
KE
Molecular Genetics, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118-2394, USA.
Li
Xiaoping
X
van Dijk
Ko Willems
KW
Havekes
Louis M
LM
Zannis
Vassilis I
VI
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D053329:Apolipoprotein E2; D001057:Apolipoproteins E / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D001693:Biological Transport, Active / Q000235:genetics; D016466:CHO Cells; D002784:Cholesterol / Q000097:blood; D006224:Cricetinae; D005260:Female; D005799:Genes, Dominant; D006801:Humans; D006949:Hyperlipidemias / Q000473:pathology; D006952:Hyperlipoproteinemia Type III / Q000378:metabolism* / Q000473:pathology; D008066:Lipolysis; D008071:Lipoprotein Lipase / Q000235:genetics / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010641:Phenotype; D010713:Phosphatidylcholines / Q000378:metabolism; D011973:Receptors, LDL / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D014162:Transfection; D014280:Triglycerides / Q000097:blood
D053329:Apolipoprotein E2; D001057:Apolipoproteins E; D008079:Lipoproteins, VLDL; D010713:Phosphatidylcholines; D011973:Receptors, LDL; D014280:Triglycerides; D002784:Cholesterol; D008071:Lipoprotein Lipase; C028694:1-palmitoyl-2-oleoylphosphatidylcholine